Homepage
Author:
Insight Molecular Diagnostics Inc.
Posted Date:
April 14, 2026
Real-World Evidence and Industry Momentum Builds for iMDx’s Flagship GraftAssure Assay
Insight Molecular Diagnostics Inc.
April 14, 2026
iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference
Insight Molecular Diagnostics Inc.
March 20, 2026
Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model Score
Insight Molecular Diagnostics Inc.
March 13, 2026
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission
Insight Molecular Diagnostics Inc.
March 3, 2026
iMDx Announces $26.0 Million Registered Direct Offering
Insight Molecular Diagnostics Inc.
February 11, 2026
